| pubmed-article:15472713 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C0596901 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C1327616 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C1840264 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C1145667 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C2825311 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C2349209 | lld:lifeskim |
| pubmed-article:15472713 | lifeskim:mentions | umls-concept:C2827421 | lld:lifeskim |
| pubmed-article:15472713 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15472713 | pubmed:dateCreated | 2005-1-19 | lld:pubmed |
| pubmed-article:15472713 | pubmed:abstractText | Recent evidence has resurrected the concept of specialized populations of T lymphocytes that are able to suppress an antigen-specific immune response. T-regulatory cells (T-reg) have been characterized as CD4+ CD25+ T cells. Previous reports describing differential gene expression analysis have shown that the glucocorticoid-induced tumor necrosis family receptor family-related gene (GITR) is upregulated in these cells. Furthermore, antibodies specific for GITR have been shown to inhibit the T-suppressor function of CD4+ CD25+ T-reg. The ligands for both mouse and human GITR have been cloned recently. We have inserted the sequences for natural, membrane-bound GITR-ligand (GITR-L) and a truncated secreted form of GITR-L (GITR-Lsol) into the adenovirus-5 genome. Coculture experiments show that cells infected with Ad-GITR-L and supernatants from cells infected with Ad-GITR-Lsol can increase the proliferation of both CD4+ CD25- and CD8+ T cells in response to anti-CD3 stimulation, in the presence, as well as in the absence, of CD4+ CD25+ T cells. The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4+ and CD8+ T cells. Both constructs were shown to inhibit tumor growth. | lld:pubmed |
| pubmed-article:15472713 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15472713 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15472713 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15472713 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15472713 | pubmed:issn | 0929-1903 | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:AcresBruceB | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:StoeckelFabie... | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:CalmelsBastie... | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:PaulStéphaneS | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:FutinNicolasN | lld:pubmed |
| pubmed-article:15472713 | pubmed:author | pubmed-author:LedouxCatheri... | lld:pubmed |
| pubmed-article:15472713 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15472713 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:15472713 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15472713 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15472713 | pubmed:pagination | 198-205 | lld:pubmed |
| pubmed-article:15472713 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:meshHeading | pubmed-meshheading:15472713... | lld:pubmed |
| pubmed-article:15472713 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15472713 | pubmed:articleTitle | Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. | lld:pubmed |
| pubmed-article:15472713 | pubmed:affiliation | Molecular Immunology Laboratory, Transgene SA, Strasbourg 67082, France. calmels@transgene.fr | lld:pubmed |
| pubmed-article:15472713 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15472713 | lld:pubmed |
